Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01533207 · ClinicalTrials.gov registry record · Phase 3
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
A Phase 3 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 3
- Development phase
- 38
- Enrollment target
NCT01533207 is a Phase 3 study that was terminated before completion, run by Gynecologic Oncology Group. The registered enrollment target is 38 participants.
The verdict
NCT01533207, a Phase 3 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 38 participants
- Enrollment target
Study Summary
This randomized phase III trial studies how well gemcitabine hydrochloride and docetaxel followed by doxorubicin hydrochloride work compared to observation in treating patients with high-risk uterine leiomyosarcoma previously removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docetaxel, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination therapy after surgery is an effective treatment for uterine leiomyosarcoma.
Interventions
- DRUG Docetaxel
- DRUG Doxorubicin Hydrochloride
- BIOLOGICAL Filgrastim
- OTHER Clinical Observation
- DRUG Gemcitabine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2012-06-04 |
| Est. Completion | 2019-02-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01533207
The ClinicalTrials.gov registry entry for NCT01533207 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT01533207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01533207 about?
NCT01533207 is a clinical study titled "Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery". This randomized phase III trial studies how well gemcitabine hydrochloride and docetaxel followed by doxorubicin hydrochloride work compared to observation in treating patients with high-risk uterine leiomyosarcoma previously removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydroc...
What is the current status of trial NCT01533207?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 38 participants. The study started on 2012-06-04. Estimated completion is 2019-02-09.
What interventions are being tested in trial NCT01533207?
The interventions under investigation include: Docetaxel (DRUG), Doxorubicin Hydrochloride (DRUG), Filgrastim (BIOLOGICAL), Clinical Observation (OTHER), Gemcitabine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01533207?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.